Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Mikhael and Cole Share Insights on Culturally Relevant Myeloma Care

October 27th 2022

Drs Mikhael and Cole discuss ways to help reduce disparities in myeloma by delivering culturally relevant care and highlight the importance of implementing shared decision-making, creating a well-informed multidisciplinary staff, and meeting patients where they are.

Advice on Delivering Culturally Competent Care for Community Physicians

October 27th 2022

Craig Cole, MD, shares advice for community physicians on providing culturally competent care to patients with multiple myeloma that embraces their beliefs, spiritualities, and ethnicities.

The Barriers to Quality Care for Black American Patients with Multiple Myeloma

October 27th 2022

A key opinion leader lists the factors that affect access to quality care for Black Americans with multiple myeloma.

Melphalan Flufenamide Plus Daratumumab Elicits PFS Benefit in Relapsed/Refractory Myeloma

October 26th 2022

The combination of melphalan flufenamide and daratumumab plus hyaluronidase-fihj and dexamethasone improved progression-free survival over daratumumab and dexamethasone alone in select patients with relapsed/refractory multiple myeloma.

Dr. Garfall of the FDA Approval of Teclistamab in Relapsed/Refractory Multiple Myeloma

October 25th 2022

Alfred L. Garfall, MD, discusses the significance of the FDA approval of teclistamab-cqyv in relapsed/refractory multiple myeloma and how this agent might fit into the treatment paradigm going forward.

FDA Approves Teclistamab-cqyv for Relapsed or Refractory Multiple Myeloma

October 25th 2022

The FDA has granted accelerated approval to teclistamab-cqyv (Tecvayli) for adult patients with relapsed or refractory multiple myeloma who have received at least 4 previous lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Dr. Varga on Current Clinical Trials for Patients with Relapsed/Refractory Multiple Myeloma

October 24th 2022

Cindy Varga, MD, discusses several exciting clinical trials at the Levine Cancer Institute for patients with relapsed/refractory multiple myeloma with acquired resistance to BCMA-directed therapy.

Addressing Healthcare Provider Bias in Multiple Myeloma Management

October 21st 2022

Joint consideration for physician bias in the management of multiple myeloma and how it can be addressed while treating patients belonging to racial and ethnic minority groups.

Improving Access to Clinical Trials in Multiple Myeloma

October 21st 2022

Centering discussion clinical trials in multiple myeloma, panelists review how to improve access to these studies for racial and ethnic minority groups.

Multiple Myeloma Clinical Trial Enrollment in the Black American Population

October 20th 2022

An expert discusses the stigmas behind clinical trials and the shockingly low rate of enrollment by Black Americans with multiple myeloma.

Spreading Multiple Myeloma Awareness in the Local Community

October 20th 2022

Dr Craig Cole explains why awareness about multiple myeloma needs to be raised in Black American communities by healthcare workers.

Dr. Paul on the Future of CAR T-Cell Therapy in Multiple Myeloma Treatment

October 18th 2022

Barry Paul, MD, discusses the emerging benefits of integrating CAR T-cell therapy into treatment paradigms for patients with relapsed/refractory multiple myeloma.

Treatments Branch Out in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

October 18th 2022

Peter Voorhees, MD, highlights important topics that his colleagues discussed at the meeting, including the important role of up-front autologous stem cell transplant and distinct adverse effects to be aware of when using different CAR T-cell therapies.

Dr. Atrash on the Evolution of BCMA-Directed Therapies in Multiple Myeloma

October 17th 2022

Shebli Atrash, MD, discusses the development and current use of BCMA-targeted antibody-drug conjugates and CAR T-cell therapies for the treatment of patients with multiple myeloma.

Proteosome Inhibitors Plus CD38 Antibodies Elicit Encouraging Responses in Multiple Myeloma

October 15th 2022

Peter Voorhees, MD, discusses key points from his presentation on proteasome inhibitors in multiple myeloma and positive data with the agents in the transplant-eligible and transplant-ineligible populations.

Improving Access to Specialty Care in Multiple Myeloma

October 14th 2022

Experts on multiple myeloma share comprehensive insight on how to build better access to specialty care for patients of racial and ethnic minority groups.

Overcoming Barriers to Early Diagnosis in Multiple Myeloma

October 14th 2022

Expert perspectives on how to improve the early detection of multiple myeloma within patients belonging to racial and ethnic minority groups.

Barriers in the Diagnosis of Multiple Myeloma for Patients

October 13th 2022

Craig Cole, MD, describes the barriers that can affect the diagnosis of multiple myeloma.

Examining the Roots of Health Disparities in Multiple Myeloma

October 13th 2022

Joseph Mikhael, MD, introduces the topic of disparities in multiple myeloma and the concept of multicultural health care.

Brentjens on the Next Chapter of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

October 10th 2022

Dr Brentjens discussed targeting the “enigmatic” GPRC5D protein, safety results with MCARH109, and the appropriate sequencing for the agent.